

Solos Endoscopy, Inc. Moves into New Offices

BOSTON, March 14, 2018 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) a provider of quality medical devices to hospitals and clinics across the country, has announced that the company is moving its operations.

Effective April 1st, Solos will begin operating out of its new offices located at 1698 Post Road East in Westport, Connecticut. Solos will occupy a 1,500sqft office unit within the Westport Place office building. For a brief period, the Company will continue to utilize its Boston facility for warehousing purposes. "The new facilities will allow for the company to expand its employee base and execute on its growth plans for 2018, subject to raising the needed additional capital", stated Dom Gatto, President of Solos Endoscopy.

About Solos Endoscopy, Inc.:

Solos Endoscopy is a medical device company providing quality innovative healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.
Investor Relations
(617) 360-9700